Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?

E-ISSN： 2212-3954|6|1|41-47

ISSN： 1574-8898

Source： Recent Patents on CNS Drug Discovery, Vol.6, Iss.1, 2011-01, pp. : 41-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?

Current Drug Safety, Vol. 8, Iss. 2, 2013-01 ,pp. : 104-113

Bentham Science Publishers

Access to resources Recommend Favorite

Do We Really Need New Trials on Fulvestrant in Prostate Cancer?

Oncology Research and Treatment, Vol. 33, Iss. 1-2, 2010-01 ,pp. : 12-13

Karger

Access to resources Recommend Favorite

Serious adverse drug events related to non‐investigational drugs in academic clinical trials: another source of safety data for risk assessment?

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 82, Iss. 4, 2016-10 ,pp. : 1069-1075

John Wiley & Sons Inc

Access to resources Recommend Favorite

The importance of monitoring adverse events in statin, and other, clinical trials

By Golomb Beatrice Alexandra

Clinical Investigation, Vol. 3, Iss. 10, 2013-10 ,pp. : 913-916

Future Science

Access to resources Recommend Favorite

Age But Not Sex Is Associated With Efficacy and Adverse Events Following Administration of Intravenous Migraine Medication: An Analysis of a Clinical Trial Database

HEADACHE, Vol. 55, Iss. 10, 2015-11 ,pp. : 1342-1355

John Wiley & Sons Inc

Access to resources Recommend Favorite